Tags

Type your tag names separated by a space and hit enter

BCL10 expression in ocular adnexal lymphomas.
Am J Ophthalmol 2005; 140(5):836-843AJ

Abstract

PURPOSE

To study BCL10 expression in ocular adnexal lymphoma in the US population and its association with clinical outcomes.

DESIGN

Institutional, retrospective study.

METHODS

Immunohistochemistry was performed with antibody against BCL10 on two tissue microarray blocks that were constructed with paraffin-embedded tissues from the same cohort of 48 patients with ocular adnexal lymphomas. The main outcomes that were measured include extraorbital involvement, recurrence rate, and time to recurrence. The median length of the follow-up period was 40 months.

RESULTS

Aberrant BCL10 expression (nuclear [moderate intensity] and cytoplasmic [weak to moderate intensity] staining) was observed in 10 of 33 cases (30.3%) of mucosa-associated lymphoid tissue (MALT) lymphoma, in 4 of 10 cases (40%) of follicular lymphoma (grade 1, 9 cases; grade 2, 1 case), in 0 of 2 cases of diffused large B-cell lymphoma, in 0 of 1 case of chronic lymphocytic leukemia/small lymphocytic lymphoma and in 1 of 1 case (100%) of mantle cell lymphoma. There were no differences in clinical parameters at examination (ie, average age, gender, site of occurrence, laterality, extraorbital involvement at diagnosis), recurrence rate, and time to recurrence for patients (MALT lymphoma or follicular lymphoma) with or without aberrant nuclear BCL10 expression.

CONCLUSION

Aberrant BCL10 expression can occur in other types of ocular adnexal lymphomas besides MALT lymphoma. Ocular adnexal MALT lymphoma may have slightly lower frequency of aberrant BCL10 expression than gastric/pulmonary MALT lymphomas that have been reported in the literature. Furthermore, aberrant BCL10 nuclear expression in ocular adnexal lymphoma does not seem to correlate with clinical outcome. Further studies that include a larger number of cases and longer follow-up period are needed to confirm our observation.

Authors+Show Affiliations

Department of Pathology, Baylor College of Medicine, Houston, Texas, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16310461

Citation

Vejabhuti, Choladda, et al. "BCL10 Expression in Ocular Adnexal Lymphomas." American Journal of Ophthalmology, vol. 140, no. 5, 2005, pp. 836-843.
Vejabhuti C, Harris GJ, Erickson BA, et al. BCL10 expression in ocular adnexal lymphomas. Am J Ophthalmol. 2005;140(5):836-843.
Vejabhuti, C., Harris, G. J., Erickson, B. A., Nishino, H., Chevez-Barrios, P., & Chang, C. C. (2005). BCL10 expression in ocular adnexal lymphomas. American Journal of Ophthalmology, 140(5), pp. 836-843.
Vejabhuti C, et al. BCL10 Expression in Ocular Adnexal Lymphomas. Am J Ophthalmol. 2005;140(5):836-843. PubMed PMID: 16310461.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BCL10 expression in ocular adnexal lymphomas. AU - Vejabhuti,Choladda, AU - Harris,Gerald J, AU - Erickson,Beth A, AU - Nishino,Ha, AU - Chevez-Barrios,Patricia, AU - Chang,Chung-Che, PY - 2005/04/01/received PY - 2005/05/19/revised PY - 2005/05/19/accepted PY - 2005/11/29/pubmed PY - 2005/12/24/medline PY - 2005/11/29/entrez SP - 836 EP - 843 JF - American journal of ophthalmology JO - Am. J. Ophthalmol. VL - 140 IS - 5 N2 - PURPOSE: To study BCL10 expression in ocular adnexal lymphoma in the US population and its association with clinical outcomes. DESIGN: Institutional, retrospective study. METHODS: Immunohistochemistry was performed with antibody against BCL10 on two tissue microarray blocks that were constructed with paraffin-embedded tissues from the same cohort of 48 patients with ocular adnexal lymphomas. The main outcomes that were measured include extraorbital involvement, recurrence rate, and time to recurrence. The median length of the follow-up period was 40 months. RESULTS: Aberrant BCL10 expression (nuclear [moderate intensity] and cytoplasmic [weak to moderate intensity] staining) was observed in 10 of 33 cases (30.3%) of mucosa-associated lymphoid tissue (MALT) lymphoma, in 4 of 10 cases (40%) of follicular lymphoma (grade 1, 9 cases; grade 2, 1 case), in 0 of 2 cases of diffused large B-cell lymphoma, in 0 of 1 case of chronic lymphocytic leukemia/small lymphocytic lymphoma and in 1 of 1 case (100%) of mantle cell lymphoma. There were no differences in clinical parameters at examination (ie, average age, gender, site of occurrence, laterality, extraorbital involvement at diagnosis), recurrence rate, and time to recurrence for patients (MALT lymphoma or follicular lymphoma) with or without aberrant nuclear BCL10 expression. CONCLUSION: Aberrant BCL10 expression can occur in other types of ocular adnexal lymphomas besides MALT lymphoma. Ocular adnexal MALT lymphoma may have slightly lower frequency of aberrant BCL10 expression than gastric/pulmonary MALT lymphomas that have been reported in the literature. Furthermore, aberrant BCL10 nuclear expression in ocular adnexal lymphoma does not seem to correlate with clinical outcome. Further studies that include a larger number of cases and longer follow-up period are needed to confirm our observation. SN - 0002-9394 UR - https://www.unboundmedicine.com/medline/citation/16310461/BCL10_expression_in_ocular_adnexal_lymphomas_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(05)00617-3 DB - PRIME DP - Unbound Medicine ER -